Source: Annual Congress 2013 –COPD mechanisms
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Calderazzo, M. B. Trujillo-Torralbo, S. Elkin, S. Johnston, P. Mallia (London, United Kingdom; Catanzaro, Italy). Clinical and inflammatory characteristics of 'unreported' COPD exacerbations. Eur Respir J 2013; 42: Suppl. 57, 2147

Member's Comments

No comment yet.

Related content which might interest you: Symptom profile of exacerbations in earlier and later COPD Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes Year: 2013 Are there any differences between Tunisian and European COPD phenotypes? Source: International Congress 2016 – Best abstracts in COPD management Year: 2016 COPD on anti-GERD therapy remains at higher risk for severe exacerbation Source: International Congress 2014 – COPD exacerbations Year: 2014 Frequency of COPD exacerbations and severity of COPD Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 MUC1-CT mediates corticosteroid responses in COPD Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 GOLD and phenotypes: The new Czech COPD guidelines Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Evaluation of the GOLD 2011 severity criteria across the COPD spectrum Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 Outcomes of COPD exacerbations - a report from the ERS COPD audit in Austria Source: Annual Congress 2013 –COPD: acute exacerbations and others Year: 2013 What is the best biomarker of COPD stability? Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 Irisin is associated with severe exacerbations of COPD independently of lung function, comorbidities and exercise capacity Source: International Congress 2015 – Notable abstracts in COPD: variety Year: 2015 Role of inflammatory biomarkers in COPD Source: International Congress 2016 – Systemic biomarkers Year: 2016 The bronchitic phenotype is associated with frequent exacerbations in COPD irrespective of chronic bacterial airway infection Source: Annual Congress 2013 –Guidelines and exacerbations Year: 2013 Do inhaled corticosteroids reduce the frequent exacerbator phenotype in COPD - A little help by a multicenter survey Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Eosinophilia as marker of outcome in hospitalised patients with AECOPD Source: Annual Congress 2013 –COPD and infections Year: 2013 The relation of comorbidities with the exacerbation severity in patients with COPD Source: Annual Congress 2013 –COPD mechanisms Year: 2013 The serum level of surfactantproteind in patients with chronic obstructive pulmonary disease, depending on the nutrtional status Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015 COPD: GOLD 2011 and implications for clinical practice Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 LATE-BREAKING ABSTRACT: Stratification of patients with COPD by frequence of exacerbations is an essential step for what to treat in COPD. - A survey in a real life COPD population Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 The relationship between 24-hour symptoms and COPD exacerbations: Results from ASSESS Source: International Congress 2014 – COPD exacerbations Year: 2014 Eosinophilic airway inflammation as a complication of COPD, and the usefulness of ICS on these cases Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016